Search

everythinglearnresearchcommunity

for

Search:↓

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Upadacitinib effectively treats severe alopecia areata and is safe.

Baricitinib is effective and safe for treating severe alopecia areata.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.

Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Alopecia areata treatment varies, with no optimal method established yet.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

People with alopecia areata often have lower vitamin D levels, which are linked to more severe and longer-lasting hair loss, but vitamin D receptor levels in the skin don't show the same pattern and don't predict treatment success.

1% anthralin ointment is effective and safe for treating severe alopecia areata in children.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.